PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples

BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Möller, Katharina, Knöll, Madeleine, Bady, Elena, Schmerder, Max Jonathan, Rico, Sebastian Dwertmann, Kluth, Martina, Hube-Magg, Claudia, Blessin, Niclas C., Mandelkow, Tim, Lennartz, Maximilian, Menz, Anne, Luebke, Andreas M., Höflmayer, Doris, Fraune, Christoph, Bernreuther, Christian, Lebok, Patrick, Uhlig, Ria, Contreras, Hendrina, Weidemann, Sören, Gorbokon, Natalia, Jacobsen, Frank, Clauditz, Till S., Steurer, Stefan, Burandt, Eike, Minner, Sarah, Sauter, Guido, Simon, Ronald, Marx, Andreas H., Krech, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986704/
https://www.ncbi.nlm.nih.gov/pubmed/36683495
http://dx.doi.org/10.3233/CBM-220030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986704/
https://www.ncbi.nlm.nih.gov/pubmed/36683495
http://dx.doi.org/10.3233/CBM-220030

Ejemplares similares